Project Grant R37CA295820
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$937K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
This $2,073,138 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports an interdisciplinary research program to discover novel tumor antigens and T-cell receptors for treating platinum-resistant high-grade serous ovarian carcinoma (HGSOC). The prime awardee, the University of California, Los Angeles (UCLA), will lead efforts to define the landscape of mRNA isoforms in platinum-resistant HGSOC, examine peptides presented to the immune...
The Defense Health Agency awarded Rutgers, The State University of New Jersey a $942,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support targeted chemotherapeutic and immunotherapeutic research for drug-resistant ovarian cancer. The three-year award beginning April 1, 2023 will fund Rutgers Biomedical and Health Sciences' investigation into medical solutions for this treatment-resistant form of ovarian cancer through innovative research...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $150,271 to the University of Maryland Baltimore County (UMBC) to investigate the role of the protein kinase ADCK5 in ovarian cancer. The 2-year project, which began on September 20, 2023, aims to gain fundamental insights into the mechanisms underlying ovarian cancer, the most lethal gynecologic malignancy in the United States. The research seeks to identify potential new...
The federal Project Grant award in the amount of $1,373,308 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to investigate the role of acetylcarnitine metabolism in promoting chemoresistance in high-grade serous ovarian carcinoma (HGSOC). The overarching goal is to map the acetylcarnitine-dependent histone acetylation axis and its contribution to homologous recombination-mediated DNA repair, as well as to evaluate whether interventions that suppress...
The National Cancer Institute awarded a $506,309 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Trustees of Indiana University, doing business as Indiana University Indianapolis, to support research on the regulation of ovarian cancer metastasis. The project aims to determine the mechanism by which microenvironmental signals activate the transcription factor c-Jun in ovarian cancer cells and cause changes in chromatin accessibility, as well as to identify the...
This $131,600 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to understand and exploit apoptotic dysregulation in ovarian cancer. The awardee, Harvard T.H. Chan School of Public Health, will: 1) Ascertain apoptotic regulation and pro-survival protein dependence in pre-malignant and malignant stages of ovarian cancer transformation; 2) Use patient-derived xenograft mouse models to assess the efficacy of combining...
This $798,512 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of an allogeneic gamma/delta "armored split" chimeric antigen receptor (CAR) T-cell therapy targeting epithelial ovarian carcinoma. The innovative therapy combines dual-antigen targeting, split costimulatory domains, and an inducible safety switch to enhance anti-tumor efficacy and safety. Key planned activities include in vitro testing of...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $157,000.00 to Rutgers, The State University of New Jersey to conduct research aimed at unveiling a novel mechanism of oncovirus-induced carcinogenesis. The key objectives are to: Validate enhancer-hijacking events associated with hepatitis B virus (HBV) integration-bridged chromosomal translocations in HBV-positive tumor samples and cell lines. Identify additional enhancer-hijacking events...
This federal Project Grant award from the National Institutes of Health's National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $612,288 to the University of Wisconsin-Madison to conduct research on the role of elevated collagen I and fibronectin in the ovarian cancer pre-metastatic niche. The 5-year project, running from December 2024 through November 2029, aims to investigate molecular, cellular, and genetic mechanisms underlying high-grade serous ovarian cancer...
The National Cancer Institute (NCI) awarded a 5-year, $1,510,463 Project Grant (CFDA 93.396 Cancer Biology Research) to The Trustees of the University of Pennsylvania (UPenn) to conduct research on how non-coding RNA and mitochondrial protein complexes regulate the function of tumor-associated macrophages (TAMs) in the tumor microenvironment. The research aims to elucidate the mechanisms by which interferons induce expression of the NDUFA4L3 gene and miR-147 microRNA in TAMs, leading to...